APG777 in Patients With Atopic Dermatitis and Evidence of Type 2 Inflammatory Comorbidities

Gold L, Silverberg J, Blauvelt A, et al

This phase 2 randomized, placebo-controlled study (APEX Part A) evaluated the efficacy and safety of the long-acting anti–IL-13 antibody APG777 in adults with moderate-to-severe atopic dermatitis, including subgroups with and without type 2 comorbidities. APG777 significantly improved disease severity compared with placebo, with high EASI-75 response rates observed across all subgroups regardless of asthma, sinonasal disease, or baseline biomarkers. The treatment was well tolerated with no new safety signals, supporting its potential as an effective therapy for atopic dermatitis independent of comorbid type 2 inflammation.